Top 200 Medicines Annual Report: Climbing Mount Humira
3 "Strong Buy" Healthcare Stocks Under $5 That Could See Outsized Gains
Lundbeck gets cold feet, axes schizophrenia drug trial
3 Healthcare Stocks Under $5 That Could See Outsized Gains
New approach to airborne disinfection uses food-coloring dyes
Amarin: Improving HCP Access Should Drive More Vascepa Sales, Says Analyst
Decentralised trials – aided by tech – could boost clinical research
FDA clears Roche Epstein-Barr virus test for transplant patients
Pfizer, BioNTech Ink Deal To Supply Canada With Potential Covid-19 Vaccine
Sight Diagnostics raises $71M Series D for its blood analyzer
FDA touts advanced manufacturing to address Covid-19 shortfalls
Novavax Pops 15% On ‘Positive’ Early Trial Data From Covid-19 Candidate
Australia Approves Co-Diagnostics' Covid-19 Test; Stock Falls On Profit-Taking
CytoDyn Scores Safety Thumbs Up For Late-Stage Covid-19 Trial
DBV craters on FDA’s peanut allergy immunotherapy rejection
National Cancer Institute designates Penn’s Abramson Cancer Center as ‘exceptional’
Regeneron: Covid-19 Antibody Combo Prevents & Treats Disease In Animals
Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients
FDA Expands List Of Dangerous Hand Sanitizers To Over 100
Rival drugmakers launch joint trial of medicines for COVID-19
Eli Lilly Kicks Off Covid-19 Antibody Trial In Nursing Home Residents
Seven plucky diagnostics companies win a $249M round of contracts after surviving NIH's Covid-19 'Shark Tank' competition
Lockdowns Imposed In Melbourne, Manila As Global COVID-19 Total Tops 18 Million: Live Updates
CRISPR Startups Give Genome Editing Several New Twists
Preparing for an influx of cell and gene therapy approvals
Immunic Spikes 35% In Pre-Market On Positive Multiple Sclerosis Data
Immunic Spikes 24% In Pre-Market On Positive Multiple Sclerosis Data
Incyte, MorphoSys Win FDA Nod For ‘Key Revenue Driver’ Tafasitamab
Red Flags Soar As Big Pharma Will Be Exempt from COVID-19 Vaccine Liability Claims
Oppenheimer: These 3 "Strong Buy" Stocks Have Over 50% Upside Potential